The Woodlands-based medical device company Autonomix Medical grossed more than $11.1 million in its recent IPO.
The company’s stock now trades on the NASDAQ market under the symbol AMIX. On February 1, company officials range the NASDAQ’s closing bell. The stock closed February 5 at $5.60 per share.
The NASDAQ listing “represents a pivotal moment in the growth of our [company] and a significant corporate milestone leading to what we believe will be an exciting future for Autonomix,” says Lori Bisson, the company’s CEO.
In the IPO, Autonomix sold nearly 2.24 million shares of common stock at $5 each. The gross amount raised excludes sales commissions and other expenses.
In a January 19 filing with the U.S. Securities and Exchange Commission (SEC), Autonomix had eyed gross IPO proceeds of more than $21.2 million — nearly half of what the company actually raised — from the sale of up to 4 million shares.
For the six-month period ended September 30, 2023, Autonomix tallied a net loss of $6.9 million and a deficit of nearly $30.5 million.
Outside investors BioStar Ventures (with a 15 percent pre-IPO stake) and Tricord Holdings (5.5 percent), according to SEC documents. Before the IPO, seven Autonomix executives and directors controlled 50.6 percent of the company’s common stock.
The first medical device being developed by Autonomix, founded in 2014, is a catheter-based microchip that the company says can detect and differentiate neural signals with about 3,000 times greater sensitivity than current technology.
On its website, Autonomix cites a potential $100 billion global market for its technology.
Initially, Autonomix’s technology is geared toward treating pain stemming from pancreatitis and pancreatic cancer. Other uses for the technology, protected by dozens of patents, include management of post-surgery pain, treatment of high blood pressure, and treatment of organ-related conditions.
A day after the January 29 IPO, Autonomix announced it had wrapped up an $8 million all-stock deal to regain exclusive worldwide rights for use of its technology in the cardiology sector. In December 2021, Autonomix granted a license to Impulse Medical for use of its technology for cardiac purposes. In exchange for 1.6 million Autonomix shares, Impulse sold back those rights to Autonomix.
“Regaining the cardiology rights to our innovative technology broadens our development opportunities and provides further optionality related to our development strategy moving forward. Looking ahead, we remain focused on our pancreatic cancer pain development program and are on track to commence our first-in-human clinical study this quarter,” Bisson says.
Autonomix says its catheter-based sensing technology is designed to sense neural signals associated with pain or disease and then target those nerves for treatment.
“Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness,” say the company, “and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.”
- Houston biotech company closes IPO in $15.25M deal ›
- Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPO ›
- Houston regenerative medicine company to IPO, move toward more human trials ›
- Houston space tech startup closes deal to IPO ›
- Houston-based robotics tech company goes public via SPAC ›